Bialystok

• Does the use of empagliflozin improve exercise capacity in patients with hypertrophic cardiomyopathy. Ended recruitment
  2024-517643-31-00 5 2022-06-22 Hypertrophic cardiomyopathy
• A clinical study that compares a treatment with Iberdomide, Daratumumab and Dexamethasone against a treatment with Daratumumab, Bortezomib, … Ended recruitment
  2024-510800-35-00 5 2022-06-17 Relapsed or Refractory Multiple Myeloma (RRMM)
• A Study to Evaluate the Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adults With Active Systemic Lupus Erythematosus (EMERALD) Ended recruitment
  2023-505635-13-00 5 2022-06-10 Systemic lupus erythematosus
• Phase 3 study of pembrolizumab vs chemotherapy in dMMR advanced or recurrent endometrial carcinoma Ended recruitment
  2023-506361-56-00 5 2022-04-01 Endometrial cancer
• A study to learn how well finerenone works; how safe it is; how it moves into, through, and out of the body; and the effects it has on the b … Ended recruitment
  2023-504884-17-00 5 2022-02-04 Proteinuria
• Clinical trial of statins CAncer preventive and Pleiotropic TherApy IN smokers with chronic obstructive pulmonary disease (COPD) Ended recruitment
  2024-516714-37-00 5 2022-01-19 Chronic obstructive pulmonary disease (COPD)
• A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast Ca … Ended recruitment
  2023-509631-37-00 5 2022-01-18 "Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Bre
• DESTINY-Breast11 will compare trastuzumab deruxtecan (T-DXd) alone or in sequence with other medications, known as THP, with standard of car … Ended recruitment
  2023-505210-18-00 5 2021-12-17 Early stage HER2-positive breast cancer (T stage >= T3, lymph node pos
• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended recruitment
  2024-510735-21-00 5 2021-11-26 Atherosclerotic cardiovascular disease (ASCVD)
• Pembrolizumab/placebo plus paclitaxel with or without bevacizumab for platinum-resistant recurrent ovarian cancer. Ended recruitment
  2023-506177-35-00 11 2021-10-23 Ovarian, fallopian tube, or primary peritoneal carcinoma.
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic … Ended recruitment
  2023-506256-25-00 5 2021-10-20 Active Psoriatic Arthritis
• ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease … Ended recruitment
  2023-506926-35-00 5 2021-09-24 Atherosclerotic cardiovascular disease, chronic kidney disease and sys
• A study to learn if dapirolizumab pegol is safe and works long-term in people with systemic lupus erythematosus Ended recruitment
  2023-506368-14-00 5 2021-09-07 Systemic lupus erythematosus (SLE)
• A Study of the Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis Ended recruitment
  2023-504734-21-00 5 2021-08-30 Psoriatic arthritis (PsA)
• Guselkumab versus Placebo for the Treatment of Psoriatic Arthritis Axial Disease in Bio-naive Participants Ended recruitment
  2023-504716-15-00 6 2021-08-06 Psoriatic Arthritis
• Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic … Ended recruitment
  2023-506752-24-00 5 2021-08-05 Locally recurrent inoperable or metastatic HR+/HER2- breast cancer, wh
• PEITHO-3 - A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolism: a randomized controll … Ended recruitment
  2024-511321-54-00 5 2021-08-04 intermediate-high-risk acute pulmonary embolism
• Study to see how good and safe Tildrakizumab is in children aged 6 to under 18 years of age with skin patches Ended recruitment
  2023-504447-14-00 10 2021-07-29 Treatment of pediatric subjects with moderate to severe chronic plaque
• AIEOP-BFM 2017 POLAND - Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia - A randomized phas … Ended recruitment
  2024-517253-27-00 5 2021-07-01 Acute lymphoblastic leukemia
• Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello- … Ended recruitment
  2023-504997-39-00 5 2021-06-14 Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2
• A Phase 2 Clinical Study to Assess the Safety and Efficacy of Deucravacitinib in Participants with Active DLE and/or SCLE Ended recruitment
  2023-504161-22-00 4 2021-06-04 Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE
• A Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropathy Ended recruitment
  2023-506525-11-00 5 2021-04-19 Primary Membranous Nephropathy (pMN)
• A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive … Ended recruitment
  2023-503568-18-00 5 2021-04-13 Early human epidermal growth factor receptor 2 (HER2) positive breast
• This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Pat … Ended recruitment
  2023-507338-26-00 5 2021-02-01 Histologically documented gastric or gastroesophageal junction adenoca

Showing 289–312 of 492 trials